ISSN 1662-4009 (online)

ey0020.8-8 | New Paradigms | ESPEYB20

8.8. Type 1 diabetes as a prototypical condition challenging what we know about sleep

AM Gregory , MK Rutter , J Ware , JJ Madrid-Valero , R Hovorka , DJ Buysse

Brief summary: This ‘Letter to the Editor’ provides a critical review on how behavioural and physiological aspects of type 1 diabetes (T1D) and its management can interfere with standard principles of good quality and duration of sleep.Quality of sleep is important for general human functioning, cognitive performance, emotional well-being, as well as immune function and cardiovascular health (1). The benefits of optimal sleep apply to everyone ...

ey0020.11-7 | Diabetes | ESPEYB20

11.7. Survival of children and youth with type 1 diabetes mellitus in Tanzania

ES Majaliwa , L Minja , J Ndayongeje , K Ramaiya , SG Mfinanga , BT Mmbaga

Brief summary: This retrospective study describes a marked increase in the survival of children and youth living with Type 1 diabetes mellitus (T1D) in Tanzania, before (1991–2004), during (2005–2010) and after (2011–2019) implementation of the Life For A Child (LFAC) and Changing Diabetes in Children (CDiC) programs.This article focuses specifically on diabetes-related mortality. It offers both a message of hope and a candid examination o...

ey0020.13-6 | Section | ESPEYB20

13.6. Multi-ancestry genome-wide study in >2.5 million individuals reveals heterogeneity in mechanistic pathways of type 2 diabetes and complications

Suzuki Ken , Hatzikotoulas Konstantinos , Southam Lorraine , Taylor Henry J , Yin Xianyong , Lorenz Kim M

In Brief: The authors report the largest genetic study to date of Type 2 diabetes (T2D), pooling genome-wide association study (GWAS) data from 2 535 601 individuals (39.7% non-European ancestry), including 428 452 T2D cases. They identified 1289 independent association signals at genome-wide significance (P<5×10−8). These T2D GWAS signals could be separated into eight nonoverlapping clusters, characterised by distinct cardiometabolic disease...

ey0015.15-8 | New mechanisms: food aversion | ESPEYB15

15.8 Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15

JY Hsu , S Crawley , M Chen , DA Ayupova , DA Lindhout , J Higbee , A Kutach , W Joo , Z Gao , D Fu , C To , K Mondal , B Li , A Kekatpure , M Wang , T Laird , G Horner , J Chan , M McEntee , M Lopez , D Lakshminarasimhan , A White , SP Wang , J Yao , J Yie , H Matern , M Solloway , R Haldankar , T Parsons , J Tang , WD Shen , Y Alice Chen , H Tian , BB Allan

To read the full abstract: Nature 2017;550:255-259Loss of appetite, and even aversion to food, is a common experience during periods of illness (e.g. infection and pyrexia) and/or treatment (e.g. chemotherapy). This responses is distinct from the body’s homeostatic mechanisms (the hypothalamic leptin receptor-AGRP-POMC-MC4R axis), which normally regulate appetite and weight gain in ch...

ey0018.2-8 | Neonatal diabetes mellitus | ESPEYB18

2.8. Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated ABCC8 Permanent Neonatal Diabetes.

P Bowman , F Mathews , F Barbetti , MH Shepherd , J Sanchez , B Piccini , J Beltrand , LR Letourneau-Freiberg , M Polak , SAW Greeley , E Rawlins , T Babiker , NJ Thomas , E De Franco , S Ellard , SE Flanagan , AT Hattersley , Neonatal Diabetes International Collaborative Group

Diabetes Care. 2021 Jan;44(1):35–42. doi: 10.2337/dc20-1520. PMID: 33184150.The key findings from this cohort of patients with ABCC8 neonatal diabetes mellitus (NDM) are: A) good glycaemic control is maintained over the long-term without any serious adverse events (including severe hypoglycaemia) despite high doses of sulphonylurea, B) some patients show improvements in neurologica...

ey0018.8-3 | Important for Clinical Practice | ESPEYB18

8.3. Modified-release hydrocortisone in congenital adrenal hyperplasia

DP Merke , A Mallappa , W Arlt , A Brac de la Perriere , A Linden Hirschberg , A Juul , J Newell-Price , CG Perry , A Prete , DA Rees , N Reisch , N Stikkelbroeck , P Touraine , K Maltby , FP Treasure , J Porter , RJ Ross

J Clin Endocrinol Metab 2021; 106(5): e2063–e2077.https://pubmed.ncbi.nlm.nih.gov/33527139/The authors report the findings of a 6-month, randomized, phase 3 trial, with a single arm extension, to investigate the efficacy, safety and tolerability of modified release hydrocortisone (MC-HC) replacement therapy versus standard glucocorticoid replacement therapy in 122 adult patients with c...

ey0018.8-9 | Clinical Trials – New Treatments | ESPEYB18

8.9. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

R Pivonello , M Fleseriu , J Newell-Price , X Bertagna , J Findling , A Shimatsu , F Gu , R Auchus , R Leelawattana , EJ Lee , JH Kim , A Lacroix , A Laplanche , P O'Connell , L Tauchmanova , AM Pedroncelli , BMK Biller

Lancet Diabetes Endocrinol. 2020; 8(9): 748–761.https://pubmed.ncbi.nlm.nih.gov/32730798/The authors report the outcomes from the pivotal phase 3 trial in patients with Cushing’s disease of osilodrostat (a potent oral inhibitor of cytochrome P450 11B1, [mitochondrial 11β-hydroxylase]). Twice-daily osilodrostat rapidly reduced mean 24-h urine free cortisol (UFC) and sustained ...

ey0018.15-2 | (1) | ESPEYB18

15.2. Interpreting type 1 diabetes risk with genetics and single-cell epigenomics

Chiou Joshua , Geusz Ryan J , Okino Mei-Lin , Han Jee Yun , Miller Michael , Melton Rebecca , Beebe Elisha , Benaglio Paola , Huang Serina , Korgaonkar Katha , Heller Sandra , Kleger Alexander , Preissl Sebastian , Gorkin David U , Sander Maike , Gaulton Kyle J

Nature. 2021 volume 594, 398–402https://www.nature.com/articles/s41586-021-03552-wThe authors report a large genome-wide association study (GWAS) of type 1 diabetes (T1D) in 18 942 cases and 501 638 controls, finding 92 T1D-associated genomic loci (59 known and 33 novel). Furthermore they analyse DNA chromatin patterns in pancreas and peripheral white blood cells to help ident...

ey0019.1-1 | Basic Science and Stem Cells | ESPEYB19

1.1. Deciphering the spatial-temporal transcriptional landscape of human hypothalamus development

X Zhou , Y Lu , F Zhao , J Dong , W Ma , S Zhong , M Wang , B Wang , Y Zhao , Y Shi , Q Ma , T Lu , J Zhang , X Wang , Q Wu

Cell Stem Cell. 2022 Feb 3;29(2):328-343.e5. doi: 10.1016/j.stem.2021.11.009. PMID: 34879244.Brief Summary: By applying single-cell RNA sequencing (scRNA-seq) to 112,376 cells of human hypothalamus ranging from 7–20 gestational weeks (GW7–20), the authors produced a spatiotemporal transcriptome atlas of human hypothalamus development and revealed critical regulatory genes control...

ey0019.8-10 | New Hope | ESPEYB19

8.10. The brain penetrant PPAR[gamma] agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy

L Rodriguez-Pascau , A Vilalta , M Cerrada , E Traver , S Forss-Petter , I Weinhofer , J Bauer , S Kemp , G Pina , S Pascual , U Meya , PL Musolino , J Berger , M Martinell , P Pizcueta

Sci Transl Med. 2021; 13(596): eabc0555. PMID: 34078742https://pubmed.ncbi.nlm.nih.gov/34078742/Brief Summary: These in vitro and in vivo studies show that the brain penetrant PPARγ agonist leriglitazone restores multiple biological pathways relevant for neuroinflammatory and neurodegenerative diseases, and particularly for X-linked adreno-leukodystrophy (X-AL...